Agilon Health director buys 81,000 company shares

Agilon Health director John William Wulf increased his stake in the company.

Rhea-AI Filing Summary

Agilon Health director John William Wulf increased his stake in the company. On 11/12/2025, he purchased 81,000 shares of agilon health, inc. common stock in open-market transactions at a weighted average price of $0.6289 per share, with individual trades ranging from $0.6251 to $0.6321.

Following this purchase, he directly beneficially owns 365,857 shares of common stock, which include restricted stock units.

Insider Trade Summary

Net Buyer: 81,000 shares

Net Buy 1 txn

Insider Wulf John William

Role Director

Bought 81,000 shs ($51K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	81,000	$0.6289	$51K

Holdings After Transaction: Common Stock — 365,857 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.6251 to $0.6321, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
2. F2. Includes restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Agilon Health (AGL) report in this Form 4?

Agilon Health reported that director John William Wulf bought 81,000 shares of common stock. The shares were acquired in open-market purchases, increasing his directly beneficially owned position to 365,857 shares, including restricted stock units.

On what date did the Agilon Health (AGL) director buy shares?

The director’s share purchase occurred on 11/12/2025. This date is listed as the transaction date for the 81,000 common shares acquired, and it marks the earliest transaction reported in this Form 4 filing for John William Wulf.

What price did the Agilon Health (AGL) director pay for the 81,000 shares?

The director paid a weighted average price of $0.6289 per share. The filing explains that the 81,000 shares were bought in multiple trades, with prices ranging from $0.6251 to $0.6321, and full trade details are available upon request.

How many Agilon Health (AGL) shares does the director own after this transaction?

After the reported purchase, the director beneficially owns 365,857 shares of common stock. The filing states that this amount is held directly and includes restricted stock units as part of his overall share position.

Is the Agilon Health (AGL) director’s ownership direct or indirect in this Form 4?

The Form 4 shows that the 365,857 shares are held as direct ownership. The ownership form column lists the holding as “D” for direct, and there is no indication of indirect ownership through other entities or accounts.

What does the Form 4 say about the price range for the Agilon Health (AGL) share purchases?

The filing notes that the price is a weighted average across multiple trades. Individual transactions for the 81,000 shares occurred at prices ranging from $0.6251 to $0.6321, and detailed trade-level data is available from the reporting person upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 07:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wulf John William

(Last) (First) (Middle)

C/O AGILON HEALTH, INC.

440 POLARIS PARKWAY, SUITE 550

(Street)

WESTERVILLE OH 43082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
agilon health, inc. [ AGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		P		81,000	A	$0.6289(1)	365,857(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.6251 to $0.6321, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

2. Includes restricted stock units.

Remarks:

	/s/ Mimi Yang, as Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.